Predictive Oncology

Predictive Oncology demonstrates long-term viability of primary live-cell tumor specimens with 100% concordance between drug response from original patient samples and cryogenically preserved samples from the same patients over time. Findings prove critical for predicting outcomes, most notably overall survival (OS), informing personalized therapies, target validation, and in silicomodeling of drug-tumor responses.  “This not only validates the utility of our biobank, but also the strength and reliability of the drug response data that we compiled over those many years. We are uniquely positioned to enable drug developers to query patient responses to their drug candidates, accounting for real-world patient heterogeneity, and to validate targets and biomarkers long before human clinical trials commence,” said Dr. Arlette Uihlein, SVP of Translational Medicine and Drug Discovery at Predictive Oncology. To learn more about how this study further validates the significance of highly reproducible drug response data, click here: https://lnkd.in/e5cxgKMC. For investors, click here: https://lnkd.in/e4vu5bgt

Predictive Oncology, Inc. Announces Initiation of Equity Analyst Coverage by H.C. Wainwright “The initiation of coverage by H.C. Wainwright marks a milestone in our efforts to be independently valued by such a highly respected analyst with specialized knowledge and critical insights into our competitive standing and growth potential,” said Raymond F. Vennare, Chief Executive Officer of Predictive Oncology. “We are grateful for this recognition and very pleased with H.C. Wainwrights ‘Buy’ recommendation.” Learn more here: https://lnkd.in/gRv5RWvZ

White Paper validates highly reproducible drug response data. Results enable AI platform to model and predict patient outcomes on historical samples.   Leveraging more than 20 years of longitudinal patient and drug response data, Predictive Oncology verified and validated that the cryopreserved tumor samples preserved in the company’s live-cell biobank continue to produce accurate drug response data that is consistent with their initial clinical testing results with 100% concordance.     These findings clearly demonstrate the fidelity of the specimens in Predictive Oncology’s biobank and the ability to connect and subsequently analyze these historical samples relative to patient outcomes. The ability to introduce patient heterogeneity in the discovery and development stages increases the Probability of Technical Success (PTS) and reduces the risk inherent in all aspects of the drug development pipeline.    To download the white paper, please visit https://lnkd.in/gfmz_Nhf. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery  #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech  #lifesciences  

In its effort to remain at the forefront of artificial intelligence in drug discovery, Predictive Oncology continues to leverage its extensive biobank of cryogenically preserved patient-derived live-cell tumor samples, across 137 different tumor types to de-risk drug discovery and accelerate drug development timelines for pharmaceutical companies involved in biomarker discovery, clinical trial optimization and target validation. By incorporating real-world applications through its proprietary artificial intelligence and machine learning platform, Predictive Oncology helps its partners make critical go/no go decisions, redirect resources or reprioritize R&D efforts to pursue parallel or contingent drug development initiatives.    To learn more about how the company has successfully demonstrated its ability to increase the Probability of Technical Success (PTS) by incorporating real-world applications, please visit us at https://lnkd.in/gvnTrtJ5. For investors, click here https://lnkd.in/gb9BepZA.    #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery  #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech  #lifesciences

Recognizing the pervasive and systemic reality of multibillion-dollar losses from late-stage clinical trial failures, Predictive Oncology recently announced the expansion of its live-cell tumor platform to de-risk drug discovery and accelerate pipeline development. The company — leveraging its artificial intelligence and machine learning capabilities —  is now mining its extensive biobank of cryogenically preserved patient-derived live-cell tumor samples, across 137 different tumor types to account for patient heterogeneity ahead of any clinical phase development work. The ability to accelerate drug development timelines would allow pharmaceutical companies to make critical go/no go decisions, redirect resources or reprioritize R&D efforts more quickly and efficiently. To learn more about how Predictive Oncology has successfully demonstrated its ability to increase the Probability of Technical Success (PTS) by incorporating real-world applications, please visit https://lnkd.in/gvnTrtJ5. For investors, click here https://lnkd.in/gb9BepZA. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech #lifesciences

In a revealing new white paper released by Predictive Oncology, the company highlights the high failure rate of late-stage clinical trials and offers a potential path forward to increase the probability of technical success, which is a key metric in target selection, clinical trial design and pipeline replenishment. One of the most persistent reasons for these failed trials is that the heterogeneity of human subjects is not introduced until clinical trials are well underway.  But what if patient heterogeneity could be introduced much earlier in the development process by leveraging artificial intelligence and active machine learning and access to an extensive biobank of cryogenically preserved patient-derived tumor samples to determine which compounds had the greatest probability of using primary patient cells, not immortalized cell lines? What if this testing approach could be completed in weeks, not years, and at a fraction of the cost of the annualized R&D budget for any one drug? Visit https://lnkd.in/gvnTrtJ5 to download the study. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #molecularbiology #oncologydrugdiscovery  #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech  #lifesciences

Reduce interference of endotoxin detection in biologics with a collaborative solution from Predictive Oncology and FUJIFILM Wako Pyrostar.   Predictive Oncology’s Dr. Chrysanty Weaver, Director of Research and Development, discusses the results of our work with FUJIFILM Wako Pyrostar where after EndoPrep™ treatment, endotoxin spike recovery increases to nearly 100% for IgG and Sushi3 biologics. Learn more at the webinar below.

Predictive Oncology today announced that the company has entered the biomarker discovery market after successful multi-year retrospective ovarian cancer study with UPMC Magee-Womens Hospital that accurately predicted both short-term and long-term survival outcomes among ovarian cancer patients. This strategic initiative further leverages the company’s AI/ML driven platform to include novel oncology biomarker discovery related to patient overall survival (OS) and drug response. Read more here [link to press release]. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #biomarker #biomarkerdiscovery #molecularbiology #oncologydrugdiscovery  #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech  #lifesciences #NASDAQ #POAI

An important new white paper, released today, highlights Predictive Oncology’s success in using artificial intelligence-powered evidence-based molecular decision-making for improved outcomes in ovarian cancer. This white paper details a multi-year collaboration between Predictive Oncology and UPMC Magee-Womens Hospital applying data-driven artificial intelligence machine learning (ML) to predict survival outcomes for ovarian high grade serous carcinoma patients (HGSC). Visit https://lnkd.in/gwzK8xZJ to download the study. #drugdiscovery #drugdevelopment #pharma #emergingtechnologies #biopharma #biomarker #biomarkerdiscovery #molecularbiology #oncologydrugdiscovery  #oncology #machinelearning #AI #marketaccess #artificialintelligence #digitaltransformation #cancerresearch #biotech  #lifesciences #POAI

Listen to our collaborator from FUJIFILM Wako Pyrostar, Timothy Francis, Senior Technical Specialist LAL Division, share about our joint effort to help biopharmaceutical companies more effectively reduce protein interference and more accurately detection of endotoxins. Contact us to learn more: https://lnkd.in/g8YKwn5x #biochemistry #microbiology #laboratory #humanhealth #endotoxins #biologicdrugproducts #LALproteincascade #LALcascade #PredictiveOncology #Fujifilm #drugsafety #labtesting